These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1908584)

  • 1. Effects of ritanserin on aversive classical conditioning in humans.
    Hensman R; Guimarães FS; Wang M; Deakin JF
    Psychopharmacology (Berl); 1991; 104(2):220-4. PubMed ID: 1908584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of buspirone with diazepam and fluvoxamine on aversive classical conditioning in humans.
    Hellewell JS; Guimaraes FS; Wang M; Deakin JF
    J Psychopharmacol; 1999; 13(2):122-7. PubMed ID: 10475716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of serotonin 5-HT(2A/2C) antagonists on associative learning in the rabbit.
    Welsh SE; Romano AG; Harvey JA
    Psychopharmacology (Berl); 1998 May; 137(2):157-63. PubMed ID: 9630002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a psychophysiological model of classical fear conditioning in healthy volunteers: influence of gender, instruction, personality and placebo.
    Guimarães FS; Hellewell J; Hensman R; Wang M; Deakin JF
    Psychopharmacology (Berl); 1991; 104(2):231-6. PubMed ID: 1876667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buspirone decreases physiological reactivity to unconditioned and conditioned aversive stimuli.
    Bond AJ; Wingrove J; Baylis M; Dalton J
    Psychopharmacology (Berl); 2003 Jan; 165(3):291-5. PubMed ID: 12420156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
    McBride PA; Mann JJ; Nimchinsky E; Cohen ML
    Life Sci; 1990; 47(23):2089-95. PubMed ID: 2125095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a psychophysiological model of classical fear conditioning in anxious patients.
    Ashcroft KR; Guimarães FS; Wang M; Deakin JF
    Psychopharmacology (Berl); 1991; 104(2):215-9. PubMed ID: 1876666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the 5HT2 antagonist ritanserin on food intake and on 5HT-induced anorexia in the rat.
    Massi M; Marini S
    Pharmacol Biochem Behav; 1987 Feb; 26(2):333-40. PubMed ID: 3106990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of a difference between ketanserin and ritanserin in central vs. peripheral serotonin receptor antagonism.
    Cohen ML; Bloomquist WL; Snoddy HD; Fuller RW
    Life Sci; 1989; 45(13):1185-9. PubMed ID: 2507847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in 5HT-related pharmacology of animal models of anxiety.
    Gardner CR
    Pharmacol Biochem Behav; 1986 May; 24(5):1479-85. PubMed ID: 2873594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of acute platelet thrombosis formation in stenosed canine coronary arteries by specific serotonin 5HT2 receptor antagonist ritanserin.
    Torr S; Noble MI; Folts JD
    Cardiovasc Res; 1990 Jun; 24(6):465-70. PubMed ID: 2117499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ritanserin facilitates anxiety in a simulated public-speaking paradigm.
    Guimarães FS; Mbaya PS; Deakin JF
    J Psychopharmacol; 1997; 11(3):225-31. PubMed ID: 9305414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of LSD, ritanserin, 8-OH-DPAT, and lisuride on classical conditioning in the rabbit.
    Welsh SE; Kachelries WJ; Romano AG; Simansky KJ; Harvey JA
    Pharmacol Biochem Behav; 1998 Feb; 59(2):469-75. PubMed ID: 9476997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of dopamine-D2 and serotonin-S2 receptors by chronic treatment with the serotonin-S2 antagonists, ritanserin, and setoperone.
    Leysen JE; van Gompel P; Gommeren W; Laduron PM
    Psychopharmacol Ser; 1987; 3():214-24. PubMed ID: 2950521
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence for serotonin-S2 receptor involvement in analgesia in humans.
    Sandrini G; Alfonsi E; De Rysky C; Marini S; Facchinetti F; Nappi G
    Eur J Pharmacol; 1986 Nov; 130(3):311-4. PubMed ID: 3098573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Action of serotonin in the medial prefrontal cortex: mediation by serotonin3-like receptors.
    Ashby CR; Edwards E; Wang RY
    Synapse; 1992 Jan; 10(1):7-15. PubMed ID: 1536032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies.
    Cortijo J; Martí-Cabrera M; Bernabeu E; Domènech T; Bou J; Fernández AG; Beleta J; Palacios JM; Morcillo EJ
    Br J Pharmacol; 1997 Dec; 122(7):1455-63. PubMed ID: 9421295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of changes in brain 5-HT activity on indicators of cortical arousal.
    Rammsayer T; Netter P
    Int Clin Psychopharmacol; 1988 Jul; 3(3):231-7. PubMed ID: 3155282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ritanserin on the rewarding properties of d-amphetamine, morphine and diazepam revealed by conditioned place preference in rats.
    Nomikos GG; Spyraki C
    Pharmacol Biochem Behav; 1988 Aug; 30(4):853-8. PubMed ID: 3147460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-related effects of selective 5-HT2 receptor antagonists on slow wave sleep in humans.
    Sharpley AL; Solomon RA; Fernando AI; da Roza Davis JM; Cowen PJ
    Psychopharmacology (Berl); 1990; 101(4):568-9. PubMed ID: 2117764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.